Genetic Technologies Ltd. (GENE)

1.68
0.13 8.40
NASDAQ : Health Technology
Prev Close 1.55
Open 1.64
Day Low/High 1.58 / 1.69
52 Wk Low/High 0.70 / 2.05
Volume 244.50K
Avg Volume 536.50K
Exchange NASDAQ
Shares Outstanding 16.24M
Market Cap 30.49M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Change Of Chief Executive Officer

Change Of Chief Executive Officer

Appointment Of Chairman

Appointment Of Chairman

Resignation Of Directors

Resignation Of Directors

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of breaking out and trading higher from current levels.

PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK

PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK

Clinically validated BREVAGenplus(R) more accurately identifies sporadic breast cancer risk

ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK

ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK

Personalized, Genetically-Based Test Enables Physicians to Tailor Breast Cancer Screening and Reduction Services Based on Individual Risk

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Shares of Genetic Technologies Ltd. (GENE) rose Monday after the molecular diagnostics company announced that two new breast health centers will start to offer BREVAGenplus®.

Stalking an Entry in RetailMeNot

Can we wait for it to tell us whether to buy or avoid it.?

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT

Findings presented at the 2014 San Antonio Breast Cancer Symposium

Why Genetic Technologies (GENE) Stock Is Spiking Today

Why Genetic Technologies (GENE) Stock Is Spiking Today

Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Interesting GENE Call For February 2014

Interesting GENE Call For February 2014

Investors in Genetic Technologies Ltd. saw new options become available today, for the February 2014 expiration.

STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE

STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE

Phenogen Sciences, Inc. Presented Study Results at the 23rd Annual National Interdisciplinary Breast Center Conference

The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment

The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment

Local Physician One of the First in Nation to Use New Breast Cancer Predictive Risk Test

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.